Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study

• DOI: 10.1007/s15010-023-02011-0
• Publication Date: 2023-03-04T16:02:35Z
• Authors: Stefano Tancredi; Arnaud Chiolero; Cornelia Wagner; Moa Lina Haller; Patricia Chocano-...; Natalia Ortega; Nicolas Rodondi; Laurent Kaufmann; Elsa Lorthe; Hélène Baysson; Silvia Stringhini; Gisela Michel; Chantal Lüdi; Erika Harju; Irene Frank; Medea Imboden; Melissa Witzig; Dirk Keidel; Nicole Probst-Hensch; Rebecca Amati; Emiliano Albanese; Laurie Corna; Luca Crivelli; Julia Vincentini; Semira Gonseth Nu...; Murielle Bochud; Valérie D’Acremont; Philipp Kohler; Christian R. Kahlert; Alexia Cusini; Anja Frei; Milo A. Puhan; Marco Geigges; Marco Kaufmann; Jan Fehr; Stéphane Cullati; ; Antonio Amendola; Alexia Anagnostop...; Daniela Anker; Anna Maria Annoni; Hélène Aschmann; Andrew Azman; Antoine Bal; Tala Ballouz; Kleona Bezani; Annette Blattmann; Patrick Bleich; Patrick Bodenmann; Peter Buttaroni; Audrey Butty; Anne Linda Camerini; Patricia Orializ ...; Prune Collombet; Diana Sofia Da Co...; Agathe Deschamps; Paola D’Ippolito; Anja Domenghino; Richard Dubos; Roxane Dumont; Olivier Duperrex; Julien Dupraz; Malik Egger; Emna El-May; Nacira El Merjani; Nathalie Engler; Adina Mihaela Epure; Lukas Erksam; Sandrine Estoppey; Marta Fadda; Vincent Faivre; Andrea Felappi; Maddalena Fiordelli; Antoine Flahault; Luc Fornerod; Cristina Fragoso ...; Natalie Francioli; Marion Frangville; Irène Frank; Giovanni Franscella; Clément Graindorge; Idris Guessous; Séverine Harnal; Emilie Jendly; Ayoung Jeong; Laurent Kaiser; Simone Kessler; Christine Krähenbühl; Susi Kriemler; Julien Lamour; Sara Levati; Pierre Lescuyer; Andrea Loizeau; Chantal Luedi; Jean-Luc Magnin; Chantal Martinez; Eric Masserey; Dominik Menges; Rosalba Morese; Nicolai Mösli; Natacha Noël; Daniel Henry Paris; Jérôme Pasquier; Francesco Pennacchio; Stefan Pfister; Giovanni Piumatti; Géraldine Poulain; Caroline Pugin; Milo Puhan; Nick Pullen; Thomas Radtke; Manuela Rasi; Aude Richard; Viviane Richard; Claude-François R...; Pierre-Yves Rodondi; Serena Sabatini; Khadija Samir; Javier Sanchis Zo...; Virginie Schlüter; Alexia Schmid; Valentine Schneider; Maria Schüpbach; Nathalie Schwab; Claire Semaani; Alexandre Speierer; Amélie Steiner-Du...; Stéphanie Testini; Julien Thabard; Mauro Tonolla; Nicolas Troillet; Agne Ulyte; Sophie Vassaux; Thomas Vermes; Jennifer Villers; Viktor von Wyl; Rylana Wenger; Erin West; Ania Wisniak; María-Eugenia Zab...; Kyra Zens; Claire Zuppinger
• Keywords: Seroprevalence

We aimed to assess the seroprevalence trends of SARS-CoV-2 antibodies in several Swiss cantons between May 2020 and September 2021 investigate risk factors for seropositivity their changes over time.We conducted repeated population-based serological studies different regions using a common methodology. defined three study periods: May-October (period 1, prior vaccination), November 2020-mid-May 2, first months vaccination campaign), mid-May-September 3, large share population vaccinated). measured anti-spike IgG. Participants provided information on sociodemographic socioeconomic characteristics, health status, adherence preventive measures. estimated with Bayesian logistic regression model association Poisson models.We included 13,291 participants aged 20 older from 11 cantons. Seroprevalence was 3.7% (95% CI 2.1-4.9) period 16.2% 14.4-17.5) 72.0% 70.3-73.8) regional variations. In younger age (20-64) only factor associated higher seropositivity. being ≥ 65 years, high income, retired, overweight or obese other comorbidities, These associations disappeared after adjusting status. Seropositivity lower measures, due uptake.Seroprevalence sharply increased time, also thanks vaccination, some After campaign, no differences subgroups were observed.